|
|
|
| Discussion on regulative effects of Zuogui Pills and Yougui Pills on immune system from the theory of vital gate water and fire |
| ZOU Jixuan1 ZHAO Pei1 SONG Ying2 CAO Xintian1 WANG Mingjing2 LIU Weiyi2 LYU Yan2 HU Xiaomei2 |
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
|
|
|
|
Abstract “Immunity” is a defense mechanism used by the body to resist foreign bodies and recognize and deal with abnormal cells. It is highly similar in function to “yang qi” in traditional Chinese medicine. And yang qi mainly originates from the vital gate. Zuogui Pills and Yougui Pills, created by Zhang Jingyue based on his theory of vital gate water and fire, are famous prescriptions for regulating and supplementing zhenyin and yuanyang of vital gate. Therefore, based on the theory of vital gate water and fire, combined with modern research progress, this paper discusses the regulatory effects of Zuogui Pills and Yougui Pills on immune system. It is found that the functions of the vital gate are highly similar to those of the central immune organs. It can be said that the zhenyin of the vital gate is the concentrated embodiment of the material basis of immune activities, and the bioactive molecules such as cytokines secreted by various cells in the bone marrow are the specific manifestations of the vital gate yuanyang. Zuogui Pills and Yougui Pills can regulate the vital gate water and fire, restore the imbalance of yin and yang to the equilibrium state of mutual root and mutual use, and play a role in regulating the body’s immune system disorder. It is feasible to use Zuogui Pills and Yougui Pills to treat some autoimmune diseases with deficiency syndrome as the main syndrome, and it is worth further exploration and popularization.
|
|
|
|
|
|
[1] 王冰.黄帝内经素问[M].沈阳：辽宁科学技术出版社，1997.
[2] 史菘.灵枢经[M].长春：时代文艺出版社，2008.
[3] 秦越人.难经[M].北京：科学技术文献出版社，1996.
[4] 孙一奎.中医非物质文化遗产临床经典读本医旨绪余[M].北京：中国医药科技出版社，2012.
[5] 孙一奎.赤水玄珠全集[M].北京：人民卫生出版社，1936.
[6] 赵献可.医贯[M].6卷.北京：人民卫生出版社，1959.
[7] 张介宾.景岳全书[M].北京：中国中医药出版社，1994.
[8] 张介宾.类经 附：类经图翼 类经附翼[M].北京：中国中医药出版社，1997.
[9] 徐镛.医学举要[M].6卷.上海：上海卫生出版社，1957.
[10] 巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社，1997.
[11] Bernstein ID，Andrews RG，Zsebo KM. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells，and the generation of colony- forming cell progeny from CD34+lin- cells cultured with interleukin-3，granulocyte colony-stimulating factor，or granulocyte-macrophage colony-stimulating factor [J]. Blood，1991，77（11）：2316-2321.
[12] Brandt J，Briddell RA，Srour EF，et al. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells [J]. Blood，1992，79（3）：634-641.
[13] Ariyama Y，Misawa S，Sonoda Y. Synergistic effects of stem cell factor and interleukin 6 or interleukin 11 on the expansion of murine hematopoietic progenitors in liquid suspension culture [J]. Stem Cells，1995，13（4）：404-413.
[14] Rasko JE，Metcalf D，Rossner MT，et al. The flt3/flk-2 ligand：receptor distribution and action on murine haemopoietic cell survival and proliferation [J]. Leukemia，1995，9（12）：2058-2066.
[15] Robinson S，Mosley RL，Parajuli P，et al. Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macrophage colony-stimulating factor acting alone or in combination [J]. J Hematother Stem Cell Res，2000，9（5）：711-720.
[16] Kobayashi M，Laver JH，Kato T，et al. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3 [J]. Blood，1996，88（2）：429-436.
[17] Piacibello W，Sanavio F，Garetto L，et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood [J]. Blood，1997，89（8）：2644- 2653.
[18] Wang Y，Huang J，Gong L，et al. The plasticity of mesenchymal stem cells in regulating surface HLA-I [J]. iScience，2019，15：66-78.
[19] Rani S，Ryan AE，Griffin MD，et al. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications [J]. Mol Ther，2015，23（5）：812- 823.
[20] Shigemoto-Kuroda T，Oh JY，Kim DK，et al. MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models：type 1 diabetes and uveoretinitis [J]. Stem Cell Rep，2017，8（5）：1214-1225.
[21] Martin-Rufino JD，Espinosa-Lara N，Osugui L，et al. Targeting the immune system with mesenchymal stromal cell-derived extracellular vesicles：what is the cargo’s mechanism of action? [J]. Front Bioeng Biotechnol，2019， 7：308.
[22] Yin K，Wang SH，Zhao RC. Exosomes from mesenchymal stem/stromal cells：a new therapeutic paradigm [J]. Biomark Res，2019，7：8.
[23] 黄晓芹，黄茜.左归丸和右归丸对低出生体重小鼠细胞干细胞抗原-1干细胞因子表达的影响[J].时珍国医国药，2014，25（12）：2884-2886.
[24] 郑轶峰，张力华，周毅.左归丸对骨髓抑制小鼠造血调控的影响[J].河北中医，2009，31（5）：759-762.
[25] 郑轶峰，张力华，秦剑，等.右归丸对骨髓抑制小鼠造血功能的影响[J].浙江中西医结合杂志，2009，19（4）：212- 215.
[26] 周莉，樊永平，王蕾，等.左归丸与右归丸对EAE大鼠血浆Th1/Th2平衡的影响[J].中西医结合心脑血管病杂志，2009，7（11）：1304-1306.
[27] 白浩成，王三斌.造血干细胞移植治疗自身免疫性疾病的研究进展[J].世界临床药物，2019，40（7）：508-513.
[28] 张学娟，孙旭燕，杨卫娟，等.人类脐带间充质干细胞的功能性与临床应用的研究进展[J].中国当代医药，2021， 28（27）：39-43.
[29] 王亚静，马丹，武泽文，等.间充质干细胞在自身免疫性疾病治疗中的临床应用进展[J].山西医科大学学报，2022， 53（2）：251-256. |
|
|
|
